Aurobindo Pharma

how big is Aurobindo Pharma?

As of October 2023, Aurobindo Pharma Ltd. has a market capitalization of ₹67,992.32 Cr and reported net sales of ₹31,723.73 Cr and net profit of ₹3,485.88 Cr over the latest four quarters. Shareholder's funds are ₹29,842.80 Cr with total assets of ₹43,858.87 Cr as of March 2024.

Market Cap: Aurobindo Pharma Ltd. has a market capitalization of 67,992.32 Cr, classifying it as a Large Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest four quarters, which includes Mar'25, Dec'24, Sep'24, and Jun'24, is 31,723.73 Cr. The sum of Net Profit for the same period is 3,485.88 Cr. This data is on a Consolidated basis.<BR><BR>Balance Sheet Snapshot: This is also on a Consolidated basis for the latest annual period ending in Mar'24. The Shareholder's Funds are reported at 29,842.80 Cr, while the Total Assets amount to 43,858.87 Cr.

What does Aurobindo Pharma do?

Aurobindo Pharma Ltd. is a prominent pharmaceutical manufacturer focused on developing and marketing active pharmaceutical ingredients, intermediates, and generic formulations. As of March 2025, it reported net sales of ₹8,382 Cr and a net profit of ₹903 Cr, with a market cap of ₹68,186 Cr.

Overview:<BR>Aurobindo Pharma Ltd. is a leading manufacturer in the pharmaceuticals and biotechnology industry, specializing in the development, manufacturing, and marketing of active pharmaceutical ingredients (APIs), intermediates, and generic formulations.<BR><BR>History:<BR>Aurobindo Pharma was incorporated on December 26, 1986, as a private limited company. It has maintained its status as a private entity and reported net sales and profit for the quarter ending March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 8,382 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 903 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 68,186 Cr (Large Cap)<BR><BR>Key Metrics:<BR>- P/E: 19.00<BR>- Industry P/E: 35<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.00<BR>- Return on Equity: 10.68%<BR>- Price to Book: 2.08<BR><BR>Contact Details:<BR>Address: Plot No 2 Maitrivihar, Behind Maithri Vanam Ameerpet Hyderabad Telangana : 500038<BR>Tel: 91-40-23736370<BR>Email: info@aurobindo.com/investorgrievanc<BR>Website: http://www.aurobindo.com

Who are in the management team of Aurobindo Pharma?

As of March 2022, Aurobindo Pharma's management team includes Chairman K Ragunathan, Executive Directors Kambam Nityananda Reddy, M Sivakumaran, and M Madan Mohan Reddy, along with several independent and non-executive directors, ensuring a diverse governance structure.

As of March 2022, the management team of Aurobindo Pharma includes the following members:<BR><BR>1. K Ragunathan - Chairman & Independent Director<BR>2. Kambam Nityananda Reddy - Executive Director<BR>3. M Sivakumaran - Executive Director<BR>4. M Madan Mohan Reddy - Executive Director<BR>5. P V Ramprasad Reddy - Non Executive Director<BR>6. Avnit Bimal Singh - Independent Non Executive Director<BR>7. Savita Mahajan - Independent Non Executive Director<BR>8. Girish Paman Vanvari - Independent Non Executive Director<BR>9. P Sarath Chandra Reddy - Independent Non Executive Director<BR>10. Santanu Mukherjee - Independent Director<BR><BR>This team comprises a mix of executive and independent directors, contributing to the governance and strategic direction of the company.

What is the bonus history of the Aurobindo Pharma?

Aurobindo Pharma's latest bonus issue was a 1:1 bonus announced on July 20, 2015, with a record date of July 21, 2015, allowing shareholders to receive one additional share for each share held.

Aurobindo Pharma has a notable bonus history, with its latest bonus issue being a 1:1 bonus announced on July 20, 2015. The record date for this bonus was July 21, 2015. This means that shareholders received one additional share for every share they held as of the record date.

Who are the peers of the Aurobindo Pharma?

Aurobindo Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Abbott India, Alkem Lab, GlaxoSmithKline Pharma, Glenmark Pharma, and Biocon. Aurobindo Pharma has a below-average growth rating and the lowest 1-year return among its peers at -6.46%.

Peers: Aurobindo Pharma's peers include Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Abbott India, Alkem Lab, Glaxosmi. Pharma, Glenmark Pharma, and Biocon.<BR><BR>Quality Snapshot: Excellent management risk is observed at Abbott India and Glaxosmi. Pharma, while Good management risk is found at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Alkem Lab, and Glenmark Pharma, and the rest. Growth ratings show Excellent growth at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is noted for Divi's Lab., Torrent Pharma, Aurobindo Pharma, Alkem Lab, and Biocon, and the rest. Excellent capital structure is seen at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Aurobindo Pharma, Abbott India, Alkem Lab, and Glaxosmi. Pharma, while Good capital structure is found at Torrent Pharma and Glenmark Pharma, and the rest.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Aurobindo Pharma has the lowest at -6.46%. Aurobindo Pharma's return is significantly lower than the highest peer return. Additionally, Torrent Pharma, Aurobindo Pharma, Alkem Lab, and Biocon have negative six-month returns.

Who are the top shareholders of the Aurobindo Pharma?

The top shareholders of Aurobindo Pharma include promoters holding 33.5%, mutual funds with 18.21%, and foreign institutional investors at 15.33%. HDFC Mutual Fund is the largest public shareholder, owning 4.33%.

The top shareholders of Aurobindo Pharma include a mix of promoters, mutual funds, and foreign institutional investors. The majority shareholders are the promoters, with Rpr Sons Advisors Private Limited and Mrs. P. Suneela Rani holding the largest stake at 33.5%. <BR><BR>In terms of institutional holdings, mutual funds hold 18.21% of the shares through 35 different schemes, while foreign institutional investors (FIIs) account for 15.33% of the holdings. The highest public shareholder is HDFC Mutual Fund, specifically through the HDFC S&P BSE 500 ETF, which holds 4.33%. Additionally, individual investors collectively own 5.47% of the company. <BR><BR>Overall, the ownership structure reflects a strong presence of both promoter and institutional investors.

When is the next results date for Aurobindo Pharma?

Aurobindo Pharma will announce its results on August 4, 2025.

Aurobindo Pharma is scheduled to declare its results on August 4, 2025.

Has Aurobindo Pharma declared dividend?

Aurobindo Pharma has declared a 400% dividend, amounting to ₹1.5 per share, with an ex-date of August 8, 2025. While recent total returns have been negative, longer-term performance shows positive growth.

Aurobindo Pharma Ltd. has declared a 400% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 400%<BR>- Amount per share: 1.5<BR>- Ex-date: 08 Aug 25<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 3 months, the price return was -11.42%, the dividend return was 0.35%, resulting in a total return of -11.07%.<BR><BR>Over the last 6 months, the price return was -9.43%, the dividend return was 0.34%, leading to a total return of -9.09%.<BR><BR>For the 1-year period, the price return was -23.64%, the dividend return was 0.27%, culminating in a total return of -23.37%.<BR><BR>In the 2-year span, the price return was 27.44%, the dividend return was 0.98%, resulting in a total return of 28.42%.<BR><BR>During the last 3 years, the price return was 88.69%, the dividend return was 2.08%, leading to a total return of 90.77%.<BR><BR>Over the past 4 years, the price return was 19.06%, the dividend return was 2.68%, resulting in a total return of 21.74%.<BR><BR>In the 5-year period, the price return was 17.94%, the dividend return was 2.84%, culminating in a total return of 20.78%.<BR><BR>Overall, Aurobindo Pharma has declared a significant dividend, but the recent total returns indicate a mixed performance, particularly in the short term, with negative returns over the last year. However, the longer-term returns show positive growth, suggesting potential recovery and value for investors.

Are Aurobindo Pharma latest results good or bad?

Aurobindo Pharma's latest results show a 5.31% increase in net sales and a 2.87% rise in net profit, indicating positive revenue growth. However, declining operating profit margins and rising costs suggest challenges in profitability, making the overall results mixed.

Aurobindo Pharma's latest results present a mixed picture. On one hand, the company achieved a net sales growth of 5.31% quarter-on-quarter and 6.28% year-over-year, reaching ₹8,285.70 crores. Additionally, the net profit increased by 2.87% sequentially to ₹848.45 crores, which is a positive sign.<BR><BR>However, the results also indicate ongoing challenges. Operating profit margins contracted to 20.37%, down from 20.57% in the previous quarter, reflecting persistent margin pressures. This decline in margins is attributed to rising employee costs, which increased significantly and outpaced revenue growth. The profit after tax margin also decreased to 10.30%, down from 10.58% sequentially.<BR><BR>Overall, while the revenue and profit figures show some growth, the compression in margins and rising costs suggest that the company is facing operational headwinds. Therefore, the results can be seen as good in terms of revenue growth but concerning regarding profitability and margin sustainability.

Is Aurobindo Pharma overvalued or undervalued?

As of November 13, 2025, Aurobindo Pharma is fairly valued with a PE ratio of 20.65 and competitive metrics compared to peers, despite a recent downgrade from attractive, showing a 5.73% return over the past week but a year-to-date decline of -9.68%.

As of 13 November 2025, Aurobindo Pharma's valuation grade has moved from attractive to fair, indicating a shift in its perceived value. The company is currently fairly valued, with a PE ratio of 20.65, an EV to EBITDA of 10.46, and a ROCE of 14.59%. In comparison to its peers, Aurobindo Pharma's valuation metrics are more favorable than those of Sun Pharma, which has a PE ratio of 36.15, and Divi's Lab, which stands at a staggering PE of 70.4.<BR><BR>Despite the recent grade change, Aurobindo Pharma's valuation remains competitive within the pharmaceutical sector, especially when compared to peers like Cipla, which is considered attractive with a PE of 22.65, and Dr. Reddy's Labs at 17.86. The company's stock has shown resilience with a 5.73% return over the past week, outperforming the Sensex's 1.40% return, although its year-to-date performance remains negative at -9.68% compared to the Sensex's 8.11%. Overall, Aurobindo Pharma's current valuation suggests it is fairly positioned in the market.

How has been the historical performance of Aurobindo Pharma?

Aurobindo Pharma has shown consistent growth in net sales and profits, with net sales increasing from ₹19,563.55 Cr in March 2019 to ₹31,723.73 Cr in March 2025, and profit after tax rising from ₹1,939.32 Cr to ₹3,515.26 Cr during the same period, indicating strong financial health and enhanced shareholder value.

Answer:<BR>The historical performance of Aurobindo Pharma shows a consistent growth trajectory in net sales and profits over the years leading up to March 2025.<BR><BR>Breakdown:<BR>Aurobindo Pharma's net sales have increased from 19,563.55 Cr in March 2019 to 31,723.73 Cr in March 2025, reflecting a strong upward trend. Total operating income has followed a similar pattern, rising from 24,855.38 Cr in March 2023 to 31,723.73 Cr in March 2025. The company's operating profit (PBDIT) also improved significantly, reaching 7,204.64 Cr in March 2025, compared to 4,009.23 Cr in March 2023. Profit before tax increased from 2,624.17 Cr in March 2023 to 5,097.98 Cr in March 2025, while profit after tax rose from 1,939.32 Cr to 3,515.26 Cr in the same period. The earnings per share (EPS) grew from 32.9 in March 2023 to 60.02 in March 2025, indicating enhanced shareholder value. On the balance sheet, total assets increased from 39,212.50 Cr in March 2023 to 48,492.01 Cr in March 2025, alongside total liabilities rising from 39,212.50 Cr to 48,492.01 Cr. Cash flow from operating activities improved from 2,386.00 Cr in March 2023 to 3,924.00 Cr in March 2025, contributing to a net cash inflow of 2,178.00 Cr in March 2025, compared to an outflow of 1,006.00 Cr in March 2024. Overall, Aurobindo Pharma has demonstrated robust growth in revenue and profitability, alongside strengthening financial health over the years.

Is Aurobindo Pharma technically bullish or bearish?

As of December 1, 2025, Aurobindo Pharma's technical trend is mildly bullish, supported by daily moving averages and a bullish weekly MACD, but tempered by mixed signals from other indicators like the monthly MACD and Bollinger Bands.

As of 1 December 2025, the technical trend for Aurobindo Pharma has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the monthly MACD is mildly bearish, indicating mixed signals across time frames. The daily moving averages are bullish, supporting the mildly bullish stance. However, the Bollinger Bands show a bearish signal on the monthly chart, which adds caution. The KST is bullish on the weekly but mildly bearish on the monthly, and both the Dow Theory and OBV indicate no clear trend. Overall, the current technical stance is mildly bullish, driven primarily by the daily moving averages and weekly MACD, but tempered by mixed signals from other indicators.

Should I buy, sell or hold Aurobindo Pharma?

Why is Aurobindo Pharma Ltd. falling/rising?

As of 02-Feb, Aurobindo Pharma Ltd. is seeing a slight rise in its stock price, currently at 1,175.10, driven by short-term outperformance despite longer-term declines. The stock has a low debt-to-equity ratio and strong institutional backing, but concerns about decreased profits and reduced investor participation may impact future stability.

As of 02-Feb, Aurobindo Pharma Ltd. is experiencing a slight rise in its stock price, currently at 1,175.10, with a change of 6.2 (0.53%) upward. This increase can be attributed to its performance today, where it outperformed the sector by 0.6%. Additionally, the stock has shown a positive return of 3.70% over the past week, contrasting with the Sensex's modest gain of only 0.16% during the same period.<BR><BR>However, while the stock is rising today, it is important to note that it has faced challenges in the longer term. Over the past month, Aurobindo Pharma's stock has declined by 3.19%, and year-to-date, it has fallen by 0.52%. Despite these declines, the stock has performed well over a three-year period, with a substantial increase of 186.68%, significantly outperforming the Sensex's 36.26% gain.<BR><BR>The stock's current performance is also supported by its low debt-to-equity ratio of 0.01 times and a return on equity (ROE) of 9.8, indicating a fair valuation. However, it is trading at a premium compared to its peers' average historical valuations, and its profits have decreased by 6.8% over the past year, which may raise concerns among investors.<BR><BR>Moreover, there has been a notable decline in investor participation, with delivery volume dropping by 80.77% against the five-day average, which could indicate a lack of confidence among retail investors. Despite high institutional holdings at 41.63%, suggesting strong backing from more knowledgeable investors, the overall liquidity remains adequate for trading.<BR><BR>In summary, Aurobindo Pharma Ltd.'s stock is rising today due to its outperformance in the sector and positive short-term trends, but it faces longer-term challenges that may affect its stability and investor sentiment.

Which are the latest news on Aurobindo Pharma?